IRIS
Armenia, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.011
NA - Nord America 754
SA - Sud America 358
EU - Europa 297
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 702
SG - Singapore 359
BR - Brasile 290
CN - Cina 210
IT - Italia 205
HK - Hong Kong 157
VN - Vietnam 82
MX - Messico 36
BD - Bangladesh 32
IN - India 31
AR - Argentina 28
GB - Regno Unito 25
TR - Turchia 21
ID - Indonesia 20
IQ - Iraq 17
ZA - Sudafrica 15
PK - Pakistan 14
RU - Federazione Russa 14
FR - Francia 12
EC - Ecuador 11
PH - Filippine 9
SA - Arabia Saudita 9
UA - Ucraina 9
UZ - Uzbekistan 9
VE - Venezuela 8
TN - Tunisia 7
CO - Colombia 6
DE - Germania 6
MA - Marocco 6
NP - Nepal 6
CA - Canada 5
PL - Polonia 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
CL - Cile 4
KE - Kenya 4
MY - Malesia 4
AZ - Azerbaigian 3
CM - Camerun 3
EG - Egitto 3
JO - Giordania 3
LB - Libano 3
NL - Olanda 3
OM - Oman 3
PE - Perù 3
SN - Senegal 3
BE - Belgio 2
BO - Bolivia 2
HN - Honduras 2
JM - Giamaica 2
KR - Corea 2
NI - Nicaragua 2
PT - Portogallo 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CU - Cuba 1
DZ - Algeria 1
ES - Italia 1
ET - Etiopia 1
FI - Finlandia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HT - Haiti 1
HU - Ungheria 1
JP - Giappone 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MN - Mongolia 1
MZ - Mozambico 1
NA - Namibia 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RE - Reunion 1
RO - Romania 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.470
Salva come PNG Salva come JPEG
Città #
San Jose 387
Singapore 196
Rome 186
Hong Kong 153
Ashburn 123
Beijing 113
Santa Clara 60
Ho Chi Minh City 36
Mexico City 26
Hanoi 21
São Paulo 19
Rio de Janeiro 17
Belo Horizonte 9
Dhaka 9
Baltimore 8
Oxford 8
Tashkent 8
Bicester 7
Secaucus 7
Baghdad 6
Brasília 6
Buffalo 6
Curitiba 6
Dallas 6
Istanbul 6
Ipatinga 5
Joinville 5
Milan 5
Quito 5
Bari 4
Da Nang 4
Erbil 4
Goiânia 4
Miami 4
Salvador 4
São Gonçalo 4
Tunis 4
Abu Dhabi 3
Amman 3
Asunción 3
Bagé 3
Bauru 3
Beirut 3
Cachoeiro de Itapemirim 3
Campinas 3
Cape Town 3
Guarulhos 3
Haiphong 3
Jakarta 3
Johannesburg 3
João Pessoa 3
Juiz de Fora 3
Kaifeng 3
Karachi 3
Kathmandu 3
Kuala Lumpur 3
Lahore 3
Ludhiana 3
Muscat 3
Novosibirsk 3
Porto Alegre 3
Pretoria 3
Santiago 3
Volta Redonda 3
Antakya 2
Bacoor 2
Bekasi 2
Boa Vista 2
Bogotá 2
Buenos Aires 2
Cabo Frio 2
Cajamar 2
Cambé 2
Can Tho 2
Caracas 2
Casablanca 2
Castanhal 2
Caxias do Sul 2
Chandigarh 2
Dakar 2
Dammam 2
Delhi 2
Diamantina 2
Durban 2
Faisalabad 2
Fortaleza 2
Franca 2
Hyderabad 2
Indaiatuba 2
Itabira 2
Kingston 2
Latisana 2
Lima 2
Los Angeles 2
Maceió 2
Managua 2
Manaus 2
Marrakesh 2
Medellín 2
Mogi das Cruzes 2
Totale 1.634
Salva come PNG Salva come JPEG
Nome #
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 84
Confirmed virological failure following enhanced adherence counseling among virally unsuppressed children and adolescents on dolutegravir-based versus other regimens: Evidence from a cohort analysis in Cameroon 66
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 55
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 52
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 51
Impact of baseline HIV-1 integrase polymorphisms on virological outcome in a large European cohort of patients starting a raltegravir-containing regimen 50
Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals 46
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study 44
Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study 43
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 42
A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naive Patients Starting a First-Line HAART 42
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 40
Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice 40
PRESTIGIO RING: "A 28-year-old highly treatmentexperienced man with vertical HIV infection on ibalizumab therapy: ART simplification perspectives" 38
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 38
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 36
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 36
A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection 36
Hepatitis B Surface Antigen Genetic Elements Critical for Immune Escape Correlate With Hepatitis B Virus Reactivation Upon Immunosuppression 36
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 36
HIV MDR is still a relevant issue despite its dramatic drop over the years 36
HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression 36
Anti-HIV-1 activity of new integrase inhibitors in lymphocytes and human primary macrophages 35
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma 35
Darunavir (DRV)/r plus raltegravir (RAL) dual regimen in multi-experienced population: long term efficacy and tolerability 35
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings 35
Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors 34
Emerging patterns and implications of HIV-1 integrase inhibitor resistance 34
BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS 34
Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens 34
Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance? 33
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 33
Selection and coevolution of mutational patterns in the HIV-1 integrase characterized by pyrosequencing analysis 32
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 32
A high HBsAg genetic complexity can influence HBV immunogenicity in the setting of acute infection 31
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors 31
Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells 31
Virological response and resistance in multi-experienced patients treated with raltegravir 31
Impact of pre-therapy viral load on virological response to modern first-line HAART 31
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy 30
Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors 30
The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing 30
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 30
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBVcoinfected patients on first-line therapy 29
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 29
P696 A COMPLEX HBV QUASISPECIES IN RT AND HBsAg CHARACTERIZES PATIENTS WITH ACUTE HEPATITIS B: A REFINED UDPS ANALYSIS 28
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype 28
Secondary Integrase Resistance Mutations Found in HIV-1 Minority Quasispecies in Integrase Therapy-Naive Patients Have Little or No Effect on Susceptibility to Integrase Inhibitors 28
HIV-1 INTEGRASE MUTATIONS, FOUND AS MINORITY QUASISPECIES IN PATIENTS NAIVE TO INTEGRASE INHIBITORS, ARE ASSOCIATED WITH DECREASED SUSCEPTIBILITY TO RALTEGRAVIR AND ELVITEGRAVIR IN VITRO 28
P681 HBsAg MUTATIONS WITH ENHANCED CAPABILITY TO EVADE IMMUNE RESPONSE ARE ASSOCIATED WITH HBV REACTIVATION DURING IMMUNOSUPPRESSION 28
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. 28
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. 28
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 28
Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers 27
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 27
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage 27
Natural raltegravir-resistance is a rare event in integrase-inhibitors naive patients, and when present, is confined to a restricted minority of secondary variants and is not associated with virological response to raltegravir 27
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 27
P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing 27
Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing 27
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 26
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 26
IMPACT OF MUTATIONS AT POSITION 135 OF HIV-1 REVERSE TRANSCRIPTASE ON VIROLOGIC RESPONSE TO A FIRST LINE NNRTI-CONTAINING HAART 26
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 26
Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries 26
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B 26
Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. 26
Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation 24
Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels 24
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients 24
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 24
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 24
P0580 : Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome 22
THE LOWEST X4 GENO2PHENO-FALSE POSITIVE RATE IS ASSOCIATED WITH GREATER CD4-DEPLETION 22
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. 22
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors 16
Totale 2.519
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.229
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.229
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20242 0 0 0 0 0 0 0 0 0 0 0 2
2024/2025826 55 0 12 104 17 11 101 97 45 28 176 180
2025/20261.691 118 10 151 127 194 156 196 80 416 240 3 0
Totale 2.519